Garadacimab-PEPD Combination to Extend Prolidase Circulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments lack effective compositions and methods that can prolong the circulation time of prolidase (PEPD) in the body, necessitating frequent administrations of anticoagulants like enoxaparin to maintain therapeutic efficacy.

Innovation Solution

Combining a specific monoclonal antibody, such as Garadacimab, that binds to Factor XII with an enzymatically inactive form of PEPD, such as PEPD-G278D, to extend PEPD's circulation time and enhance its anti-cancer effects without the need for frequent anticoagulant administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If enoxaparin is administered frequently to maintain therapeutic efficacy of PEPD, then anti-cancer effect is improved, but treatment complexity and patient burden increase

Engineering Contradiction:

Improveanti-cancer effectVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses Factor XIIa as an intermediary mechanism. By administering a Factor XIIa inhibitor, the patent creates a protective environment that prevents PEPD degradation. This intermediary approach allows PEPD to remain stable in circulation without requiring frequent anticoagulant administrations, thus reducing treatment complexity while maintaining anti-cancer efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary action by administering the Factor XIIa inhibitor before PEPD treatment. This pre-treatment establishes protective conditions that prevent PEPD degradation from the outset, extending PEPD circulation time and eliminating the need for frequent dosing adjustments during treatment.

Inventive Principle:

Principle #10Preliminary action

2Duration of action of moving object

If PEPD circulation time is extended through Factor XIIa inhibition, then drug administration frequency is reduced, but anticoagulant management complexity increases

Engineering Contradiction:

ImprovePEPD circulation timeVSAvoidanticoagulant management

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The patent employs a Factor XIIa inhibitor that serves multiple functions: it extends PEPD circulation time by preventing degradation, and simultaneously manages coagulation balance. This multi-functional approach eliminates the need for separate anticoagulant management protocols, reducing overall treatment complexity while achieving extended PEPD circulation.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Productivity

If a single dose of Garadacimab is used to maintain PEPD-G278D levels, then treatment frequency is reduced, but drug stability and efficacy consistency become challenging

Engineering Contradiction:

Improvetreatment efficiencyVSAvoiddrug stability

Core Design Contradiction:

ProductivityVSStability of the object's composition

Solution Approach 1:

The patent applies beforehand cushioning by using the Factor XIIa inhibitor to create a protective environment that cushions PEPD-G278D against degradation. This pre-established protection ensures that even with single-dose administration, PEPD-G278D maintains stable therapeutic levels throughout the extended circulation period, ensuring consistent efficacy.

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

A single dose of Garadacimab effectively maintains therapeutic levels of PEPD-G278D in circulation for up to 28 days, achieving comparable anti-tumor activity to daily enoxaparin treatment, thereby reducing the frequency of drug administration.

Implementation Method 1

Combining a specific monoclonal antibody, such as Garadacimab, that binds to Factor XII with an enzymatically inactive form of PEPD

Methodology Applied

Scientific EffectProtein-protein binding:

Implementation Method 2

Combining a specific monoclonal antibody, such as Garadacimab, that binds to Factor XII with an enzymatically inactive form of PEPD, such as PEPD-G278D, to extend PEPD's circulation time

Methodology Applied

Scientific EffectEnzymatic inhibition:

Implementation Method 3

achieving comparable anti-tumor activity to daily enoxaparin treatment

Methodology Applied

Scientific EffectAnti-cancer therapeutic effect:

Data Source

PatentUS20260055208A1Combination of garadacimab and prolidase for cancer therapy

Publication Date: 2026.02.26 HEALTH RESEARCH INC

AI summary

A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.